Login to Your Account



Pfizer’s Refocus May Bring Clarity for Lpath

By Marie Powers
Staff Writer

Wednesday, October 9, 2013
Lpath Inc. moved quickly to digest the disappointment that partner Pfizer Inc. plans to divest “a number of” its ophthalmology R&D assets, including its exclusive option for a global license to develop and commercialize Lpath’s wet age-related macular degeneration (AMD) candidate Isonep.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription